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Abstract: Age-related macular degeneration (AMD), one of the leading causes of blindness world-
wide, causes personal suffering and high socioeconomic costs. While there has been progress in the 
treatments for the neovascular form of AMD, no therapy is yet available for the more common dry 
form, also known as geographic atrophy. We analysed the retinal tissue in a mouse model of retinal 
degeneration caused by sodium iodate (NaIO3)-induced retinal pigment epithelium (RPE) atrophy 
to understand the underlying pathology. RNA sequencing (RNA-seq), qRT-PCR, Western blot, im-
munohistochemistry of the retinas and multiplex ELISA of the mouse serum were applied to find 
the pathways involved in the degeneration. NaIO3 caused patchy RPE loss and thinning of the pho-
toreceptor layer. This was accompanied by the increased retinal expression of complement compo-
nents c1s, c3, c4, cfb and cfh. C1s, C3, CFH and CFB were complement proteins, with enhanced dep-
osition at day 3. C4 was upregulated in retinal degeneration at day 10. Consistently, the transcript 
levels of proinflammatory ccl-2, -3, -5, il-1β, il-33 and tgf-β were increased in the retinas of NaIO3 
mice, but vegf-a mRNA was reduced. Macrophages, microglia and gliotic Müller cells could be a 
cellular source for local retinal inflammatory changes in the NaIO3 retina. Systemic complement and 
cytokines/chemokines remained unaltered in this model of NaIO3-dependent retinal degeneration. 
In conclusion, systemically administered NaIO3 promotes degenerative and inflammatory pro-
cesses in the retina, which can mimic the hallmarks of geographic atrophy. 
Keywords: retinal degeneration; geographic atrophy; sodium iodate; local complement; inflamma-
tion; innate immunity; mouse 
 
1. Introduction 
Dysfunctional retinal pigment epithelium (RPE) and degenerated neurosensory ret-
ina play a central role in the pathobiology of age-related macular degeneration (AMD), 
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the leading cause of blindness among the elderly in Western societies [1]. The oxidative 
events and inflammation drive the pathological changes in the retina and RPE during de-
generation [2,3]. This is seen in animal studies, which were performed to elucidate the 
molecular interplay of oxidative stress and tissue-specific complement activation in the 
eyes [4]. Furthermore, after the discovery of genetic risk variants in several complement 
pathway genes, the innate immunity was emphasised as an important mechanism in 
AMD [5]. Thereby, diverse components of the immune system, including resident micro-
glia and recruited macrophages, inflammatory activators and pathways, especially from 
the complement cascade, as well as an activated inflammasome, are involved [6]. The so-
dium iodate (NaIO3) model mimics the aspects of geographic atrophy [7]. Upon systemic 
administration, NaIO3 specifically targets the RPE, resulting in its patchy loss via necro-
sis/necroptosis [8,9] and subsequent apoptosis of adjacent photoreceptors [7,10]. Oxida-
tive stress and multiple caspase-dependent and -independent cell death pathways have 
been identified in retinal degeneration induced by NaIO3 [11]. Furthermore, the increased 
expression of tissue modulators, including stromal cell-derived factor-1 (SDF-1), hepato-
cyte growth factor (HGF) and leukaemia inhibitory factor (LIF), have been found in 
NaIO3-affected retinas [12]. A cellular response of the immune system, including the acti-
vation of macrophages, is involved as well [13]. Furthermore, the complement system as 
a pathway of the innate immune system has been observed to be upregulated after NaIO3 
treatment in vitro and in vivo [14,15]. 
 In this study, a patchy RPE loss causing photoreceptor apoptosis was associated 
with the accumulation of classical (C1s and C4) and alternative (CFH and CFB) comple-
ment components in the retina, converging in the modulation of the complement path-
way, as indicated by the accumulation of C3 in the retinal tissue. In addition, a local rise 
in chemokines was observed. Systemic inflammatory changes could not be detected. In 
sum, this suggested a retinal and not a blood-derived origin of the local rise in inflamma-
tory mediators, even though NaIO3 was administered systemically. Microglia, monocytes 
and gliotic Müller cells could be the main source of inflammatory proteins in the retina. 
2. Results 
2.1. NaIO3-Induced Retinal Degeneration 
To investigate the immunological consequences of damaged RPE in a mouse model 
of retinal degeneration, systemic NaIO3 administration was used to disrupt the integrity 
of the RPE cell layer (Figure 1). Due to a high variability in previous studies using NaIO3 
and the varying oxidising potency of this agent, a confirmation of retinal degeneration for 
each NaIO3 study cycle was needed. In the present study, the intravenous application of 
NaIO3 resulted in the formation of RPE cell agglomerations (blebs) at day 3 and RPE dis-
ruption at day 10 (Figure 1A). 
As a secondary effect, degeneration of the photoreceptor cells was observed (Figure 
1), as they depend on an intact RPE to maintain their physiological metabolism. On day 3 
following the treatment, the photoreceptor segments decreased in length, and at day 10, 
they were hardly detectable (Figure 1A). The number of photoreceptor nuclei significantly 
decreased in the NaIO3-treated mice at day 3 and continued at day 10 in the central retina, 
while their number in the untreated control mice did not change (Figure 1B). 
However, when evaluated longitudinally at the full length, the pattern of degenera-
tion within a single retina was observed to be nonuniform (Supplementary Figure S1A): 
the zones of normal retinal morphology alternated with the areas of RPE and photorecep-
tor degeneration, a feature of NaIO3 treatment commonly described as “patchy RPE loss” 
[16–18]. Further, the blood–retinal barrier was at least partly intact, as antibodies pene-
trating from the systemic bloodstream into the retinal tissue were not observed (Supple-
mentary Figure S1B). 




Figure 1. Time course of NaIO3-induced retinal degeneration. (A) H&E staining of murine retinal cross-sections at three 
(D3) and ten (D10) days following the NaIO3 treatment showed a disruption of the RPE layer, clustering of the RPE cells 
(white arrows) and photoreceptor degeneration. The photoreceptor segments (PS) were reduced at three days and nearly 
completely missing ten days after the treatment (red arrows), but also, the thickness of the outer nuclear layer (ONL) 
decreased substantially (green arrows). NFL, nerve fibre layer; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, 
inner nuclear layer; OPL, outer plexiform layer. Scale bar: 50 µm. (B) The number of photoreceptor nuclei per 60-µm 
retinal section was counted to quantify the progress of degeneration. A two-way ANOVA with Bonferroni post-tests 
showed reduced photoreceptor numbers in treated versus untreated mice (* p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 
0.0001). 
2.2. NaIO3 Treatment Increased Retinal Complement mRNA 
Systemically applied NaIO3 caused degeneration of the RPE and subsequent retinal 
degeneration. We then aimed to assess the associated inflammatory effects of the NaIO3 
treatment in the murine neurosensory retina. The RNA-seq analysis in the retinas revealed 
an upregulation of multiple complement component mRNAs in NaIO3 retinas compared 
to those of the controls (Figure 2A and Supplementary Figure S2). 
 
Figure 2. Increase in the mRNA expression of the complement components in the retina following NaIO3 treatment. (A) 
The transcript quantity of the components of the complement pathway (GO: 0006956) was changed in the retinas after the 
NaIO3 treatment at day 3. Nodes are the genes with their connections as defined in STRING database version 10, and the 
colour is given by the fold change (log2FC = 4) of the regulation (red = up, white = no regulation). (B) The fold change 
(log2) mRNA expression levels of the general (c3 and c3ar1), classical (c1s and c4) and alternative (cfb) pathway components 
were analysed in independent experiments using either RNA-seq or RT-qPCR. The retinal tissue was harvested at day 3 
(RNA-seq analysis, n = 5) or day 3 and day 10 (RT-qPCR, n = 6) after NaIO3 application. RNA-seq gene expression was 
normalised to the overall gene set. The RT-qPCR expression was normalised to the idh3b reference mRNA. Fold change in 
the expression (compared to the untreated control, line at y = 0) was calculated on the logarithm to base 2. The gene 
expressions of treated versus untreated retinas were evaluated using ordinary one-way ANOVA and Tukey’s multiple 
comparisons test (* 0.01 < p < 0.05, ** 0.001< p < 0.01, *** 0.0001 < p < 0.001 and **** p < 0.0001). 
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The influence of NaIO3 on the expression of complement genes was confirmed in RT-
qPCRs from isolated retinas, showing a consistent complement mRNA increase, including 
that of c3, c3ar1, c1s and c4 in NaIO3 mice compared to the controls on day 3 (Figure 2B). 
The c1qb and cfp transcripts were only significantly upregulated in the RNA-seq evalua-
tion. In contrast, the cfb levels were significantly increased in the RT-qPCR experiments 
but were not detected in the RNA-seq analysis. To investigate the more long-term effects 
of NaIO3; in addition to day 3, day 10 post-treatment was also evaluated by RT-qPCR 
(Figure 2B). Most components upregulated three days post-NaIO3 were still expressed at 
significantly higher levels than in the control retinas, except for c1s mRNA, which re-
turned to the control levels on day 10.  
2.3. NaIO3 Treatment Promoted Retinal Complement Deposition 
C3, the complement component that is central to all three complement pathways, 
was analysed at the protein level to confirm the RNA expression results (Figure 3). Com-
parative Western and Simple Western™ blots were performed on the retinal protein ex-
tracts in order to accommodate the different sample availability. Thereby, C3 was detected 
at ~115 kDa in all the neurosensory retina samples of both untreated and NaIO3-treated 
mice. We confirmed increased C3 protein levels in NaIO3-treated mouse retinas at day 3 
(Figure 3A,B). However, and in contrast to the RNA data (Figure 2), the C3 protein signals 
returned to the baseline levels at day 10. The immunohistochemical staining (IHC) of C3 
revealed an accumulation of proteins at the photoreceptor outer segment (POS) layer of 
NaIO3-treated mouse retinas (Figure 3C). This distinct C3 accumulation was only present 
on day 3. Ten days post-treatment, a faint staining remained detectable in conjunction 
with almost completely degenerated POS (see Figure 1).  
 
Figure 3. The C3 protein signals in murine neurosensory retina were increased after the NaIO3 treatment. (A) The protein 
levels of the complement component C3 were significantly increased at day 3 after the NaIO3 treatment in all the samples 
compared to the untreated control using Simple WesternTM technology. Full blots are shown in Supplementary Figure 
S3A. (B) The Western blot signals of C3 in the retinal protein extracts of NaIO3-treated mice under waning conditions were 
increased three days after treatment. The C3 protein levels were comparable to the untreated controls at day 10. GAPDH 
was used as a housekeeping protein. The intensity of the C3 signal in 3A and 3B was measured using ImageJ software. * 
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0.01 < p < 0.05, ** 0.001< p < 0.01 and *** 0.0001 < p < 0.001 (one-way ANOVA, Tukey’s multiple comparisons test). The full 
blots are shown in Supplementary Figure S3B. (C) The immunohistochemical stainings of C3 and DAPI three days and 
ten days after the NaIO3 treatment showed C3 accumulation in the POS at day 3, whereas the signal decreased after ten 
days. At this point in time, the ONL and PS thickness were reduced (see, also, Figure 1). Scale bar: 50 µm. 
To determine whether NaIO3 also enhances the systemic activation of the comple-
ment system, levels of the anaphylatoxin C3a were evaluated in mouse serum by ELISA 
(Supplementary Figure S4), but no changes of the systemic levels of C3a were detectable 
ten days following intravenous NaIO3 injection compared to untreated mice (serum of day 
3 was not available). Additionally, to the increased expression of complement component 
C3 post-NaIO3 treatment; also, the mRNA of the classical/lectin pathway components c1s 
and c4 were significantly increased (Figure 2). This corresponded to the respective protein 
levels in IHC stainings in the murine retina (Figure 4A,C). 
 
Figure 4. Classical pathway proteins C1s and C4 accumulated in NaIO3 damaged the retinas. (A) C1s immunoreactivity 
(green) was localised (white arrows) to the ONL at three days after the NaIO3 treatment. At ten days, no specific C1s 
staining remained visible. DAPI staining (blue) delineated cell nuclei. (B) C1s protein levels were not changed in the Sim-
ple WesternTM three days after the NaIO3 treatment. (C) C4 (green) was observed in the nerve fibre layer (NFL) ten days 
following the NaIO3 treatment. In contrast, no distinct C4 staining was visible at day 3. Scale bar: 50 µm. (D) C4 cleavage 
products C4d (47 kDa) and iC4b (61 kDa) were increased at day 3 after the NaIO3 treatment in all samples compared to 
the untreated control using Simple WesternTM technology. (B,D) Intensity of the signals was measured using ImageJ soft-
ware. * 0.01 < p < 0.05 (one-way ANOVA and Tukey’s multiple comparisons test). The full blots are shown in Supplemen-
tary Figure S3C,D. 
Three days after the treatment, the classical pathway initiator protein C1s were selec-
tively upregulated in the ONL, apparently close to the photoreceptor nuclei (Figure 4A). 
Ten days post-NaIO3, C1s staining disappeared, but C4 accumulated in the innermost part 
of the retina, the ganglion cell layer and nerve fibre layer, respectively (Figure 4C). Simple 
Western™ studies confirmed C4d and iC4b accumulation in the retina three days after 
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NaIO3 (Figure 4B and Figure 4D, respectively) but did not disclose the changes in the C1s 
levels shown with IHC.  
Finally, changes in the mRNA levels of cfb (significant increase) but not for cfh (not a 
significant increase) were observed in NaIO3-treated mice (Figure 2). Both are components 
of the alternative pathway. The protein analysis confirmed these findings for CFB but not 
for CFH (Figure 5), as both proteins were significantly increased in the retinas three days 
after the systemic NaIO3 application. 
 
Figure 5. Alternative pathway component CFB and CFH protein levels were increased after the 
NaIO3 treatment. (A) The CFB (~110 kDa) protein levels were increased at day 3 after the NaIO3 
treatment in all the samples compared to an untreated control using Simple WesternTM technology 
for detection. (B) Complement inhibitor CFH (~162 kDa) accumulated in the neurosensory retina of 
NaIO3-treated mice compared to the control. (C) Retinal degeneration using NaIO3 resulted in CFH 
deposition in the photoreceptor outer segment layer shown in immunohistochemical stainings. An 
overlapping with microglia marker IBA-1 was observed. (A,B) GAPDH was used as a housekeeping 
protein. The intensity of the protein signal was measured using ImageJ software. ** 0.001< p < 0.01 
(unpaired, nonparametric Mann–Whitney t-test). The full blots are shown in Supplementary Figure 
S3E,F. 
In addition to the complement component analysis, the systemic NaIO3 treatment 
had a local effect on the retinal chemokine/cytokine status. Chemokines ccl-2 and ccl-3 
were highly upregulated three and ten days after NaIO3 in the RNA-seq and RT-qPCR 
analyses (Figure 6), and a similar trend was observed for ccl-5. The expression of proin-
flammatory cytokine il-1β increased compared to the control levels in one of the two tran-
scription determining techniques, and for il-33, minimal changes were also determined. 
Consistently, the mRNA levels (as determined by RNA-Seq and RT-qPCR) of the multi-
functional cytokine tgf-β showed an upward trend in response to NaIO3, whereas vegf-a, a 
proangiogenic factor, was reduced three days after the NaIO3 treatment and returned to 
the control levels on day 10.  




Figure 6. NaIO3 increased the retinal transcription of the chemokines and cytokines. RNA-seq (day 3, green) and RT-qPCR 
analysis (day 3, red; day 10, blue) of the ccl-2, 3, 5, il-1β and tgf-β expression showed a significant upregulation after the 
NaIO3 treatment. Il-33 was not significantly upregulated, whereas vegf-a was decreased on the mRNA level at day 3 fol-
lowing the treatment. The expression was normalised to the overall gene set (RNA-seq) or idh3b reference mRNA (RT-
qPCR), and the fold change in the expression (compared to the untreated control, line at y = 0) was calculated on the 
logarithm to base 2. * 0.01 < p < 0.05, ** 0.001< p < 0.01, *** 0.0001 < p < 0.001 and **** p < 0.0001 (ordinary one-way ANOVA 
and Tukey’s multiple comparisons test). 
To further evaluate to what extent intravenously applied NaIO3 caused systemic in-
flammatory dysregulation, the serum cytokine protein levels were determined by multi-
plex ELISA (Supplementary Figure S5). For the tested chemokines (CCL-2, CCL-3 and 
CCL-5) and cytokines/growth factors (IL-1β and VEGF-A), no significant alteration of the 
serum concentrations ten days after NaIO3 treatment were observed.  
Increased inflammatory signalling in the retina is often associated with microglia ac-
tivation, monocyte invasion and Müller cell gliosis. Indeed, we found subretinal micro-
glia/monocytes associated with the PR outer segments three days after treatment (Figure 
7A). The outer segments seem to become opsonised by C3b (compared to Figure 4) and 
phagocytised. After ten days, the outer segments were almost completely degraded, and 
no IBA1-positive cells were present in this region anymore. Müller cell gliosis at day 10 
was a consequence in the damaged retinas (Figure 7B).  
In summary, systemic NaIO3 application caused damage of the RPE and, subse-
quently, the neurosensory retina involving proinflammatory signalling via the local com-
plement components and chemokines. Thereby, early complement proteins such as C3, 
C1s, CFH and CFB showed an increased deposition at day 3, whereas the late complement 
component C4 was involved in retinal degeneration at day 10. 




Figure 7. Glia cells were activated in the NaIO3-damaged retina. (A) Microglia/monocytes (arrows) migrated into the pho-
toreceptor outer segment layer at day 3 following the NaIO3 treatment and were localised in the IPL at day 10. (B) GFAP 
(white), a marker for activated Müller cells, was enhanced in the GCL after NaIO3 treatment during the investigated pe-
riod. Scale bar: 20 µm. 
3. Discussion 
3.1. Validation of the NaIO3-Induced Retinal Degeneration Model  
Systemically applied NaIO3 has been frequently used to investigate murine retinal 
degeneration. While the cause of morphological changes has been quite well-described 
over the past few decades [7], research defining the inflammatory consequences of NaIO3 
treatment has only come into focus recently [12,15]. 
The impact of different doses of NaIO3 in mice has been extensively described in the 
literature [10,19]. The main conclusion was that a low dose only has a temporary effect on 
the function of the retina and does not lead to extensive changes in the morphology. An 
intermediate dose has been described to cause a “patchy” RPE cell loss with a subsequent 
degeneration of the photoreceptor cells, while a large dose inevitably leads to complete 
destruction of the retinal structure and function in a short amount of time. Variations be-
tween published studies are due to different application methods (intraperitoneal or in-
travenously) but also due to the unstable character of the chemical, NaIO3, itself. There-
fore, it is important that each study proves the potency of the NaIO3 batch before any 
treatment studies are performed. We could confirm the patchy RPE cell loss, as well as the 
degeneration of the overlying photoreceptors in our model. A validated intermediate dose 
was then used for the analysis of the complement pathway and other inflammatory com-
ponents. 
3.2. The Complement System in the Eye and Its Involvement in NaIO3-Induced Retinal 
Degeneration 
As the complement system is an integral part of the innate immune system, it is also 
involved in inflammatory processes causing retinal degeneration in diseases like AMD, 
glaucoma and diabetic retinopathy. In the eye, as a partially immune-privileged compart-
ment of the human body with a tight blood–retina barrier, the ocular tissue is required to 
produce a large number of innate immune system proteins itself, while other organs can 
rely on the supply from the liver [20]. This is especially true for the many components of 
the complement system, which, in fact, is a crucial pillar for innate immunity [21]. In line 
with this, our analyses of the retinal tissue in the acute phase of the NaIO3 treatment in-
duced retinal degeneration and showed a significant upregulation of complement com-
ponents. We conclusively demonstrated that the central complement protein C3 was sig-
nificantly upregulated at the transcript and protein levels upon the NaIO3 treatment—a 
finding that served as a quality control for our model and was complementary to previous 
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studies [12,13,15,22]. In addition, while C3 is the central connecting factor of the comple-
ment cascade, it does not lead to inflammatory processes by itself, and its interaction with 
additional complement proteins is always needed. We demonstrated recently that mainly 
complement components of the classical and the alternative pathways are expressed in 
healthy mouse retinal tissue [21], while the components of the lectin pathway (e.g., 
MASP1) were only expressed at very low levels or were not detectable at all. We could 
confirm these findings with our presented RNA-seq analysis. Interestingly, CFB was only 
detected by qPCR and not in RNA-seq, but as others described its presence in the mouse 
retina, the lack of detection in our analysis might be due to different technical preferences 
[23]. However, there is also evidence that the liver serves as the main source of ocular CFB, 
and very little if any expression is found in healthy eyes [24]. 
In the classical pathway, the initial components leading to an activation of the down-
stream cascade are C1q, C1s and C1r. In the RNA-seq analysis of the retinal tissue, these 
C1 complex components were, in fact, upregulated after the treatment with NaIO3. For 
c1s, these results were also confirmed by qPCR, and via immunostaining, an accumulation 
at the ONL was demonstrated. Another crucial component of the classical pathway down-
stream of C1 is C4, whose expression in the retina was also significantly increased after 
NaIO3 application. Katschke et al. (2018) also described a similar upregulation of various 
complement factors in the NaIO3 model [25]. They found an accumulation of C1q/C3/C4 
at the level of the photoreceptor outer segments. A comparable complement accumulation 
was observed in the retina of 26-month-old (aged) mice [26]. Luo et al. showed c1s/c4 ex-
pression in the mouse retina, including RPE/choroid under physiologic conditions and a 
significant increase after treatments with inflammatory cytokines, including interferon 
(IFN)-γ or tumour necrosis factor (TNF)-α [27]. 
Activation of the alternative pathway is driven by CFB, which was upregulated on 
the RNA level, as well as with Simple Western on the protein level after NaIO3 treatment. 
These results were comparable with published data from other groups regarding the de-
tection of CFB under aged and inflammatory conditions [26,27]. The cell-type specific 
complement expression in healthy and diseased mouse retina was already shown by us 
in another retinal degeneration mouse model [21]. 
In the context of retinal complement activation, the complement inhibitor CFH has a 
pivotal role during pathological events. Single nucleotide polymorphisms in the CFH 
gene are associated with an increased risk for AMD, and studies with cfh−/− mice have 
shown a pathological accumulation of debris in CFH-deficient RPE cells [26,28]. Here, we 
found no significant changes in the cfh mRNA expression but detected a considerable drop 
in the protein level. As the CFH protein has been mainly associated with the basal side of 
RPE cells [29], there is the possibility that the protein originates from the bloodstream. As 
the levels of the complement components are very high in the serum, and it is known that 
NaIO3 compromises the blood–retina barrier, we cannot exclude that at least some of the 
detected proteins stem from the blood circulation. However, as shown by us earlier, the 
Bruch’s membrane is thickened but still intact after the NaIO3 treatment [11]. This was 
also underscored by the fact that we could not detect any mouse IgG in the retina. Fur-
thermore, the fact that the mRNA levels are upregulated in the ocular tissue itself—in 
some cases, to a very high level (16-fold increase for C3)—implies the presence of a tissue-
specific activation cascade. 
3.3. Inflammatory Processes Induced by NaIO3 
The NaIO3-induced destruction of the retina is mediated by necrosis/necroptosis and, 
therefore, induces local inflammation [11]. Notably, the opsonisation of dying cells by 
complement components leads to clearance of the debris by the phagocytes. This can be 
associated with other inflammatory processes, e.g., immune cell activation and cyto-
kine/chemokine increase, which can further aggravate the retinal degenerative processes. 
Importantly, the serum cytokine/chemokine levels were not significantly altered in this 
study. Similar observations were made by others [25,30]. However, we detected increased 
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retinal cytokine/chemokine expression levels in the NaIO3 model. Coincidently, aged mice 
also showed an increased retinal CCL-2 secretion in a previous study [26]. In addition, to 
upregulated chemokines, the mRNA of il-1β was also increased. In accordance with the 
previous publications, IL-1β is the main downstream effector of the inflammasome and 
involved in NaIO3 pathogenesis [13,30,31]. The inflammasome is also known to activate 
caspase 1, which has been found significantly upregulated in NaIO3-mediated human RPE 
cell death [32]. The detected chemokines are directly involved in the recruitment of im-
mune cells to the site of degeneration, as we have also shown with a staining for mono-
cytes and microglia. 
4. Materials and Methods 
4.1. NaIO3 Treatment 
Experiments were conducted with 6 to 8-week-old male and female C57BL/6J mice 
(Charles River Laboratories, Sulzfeld, Germany). The mice were kept in individually ven-
tilated cages (IVC; Tecniplast, Gams, Switzerland) at a temperature of 22 °C, humidity 
50% and a 12-h/12-h light cycle with food and water ad libitum. A sterile 1% NaIO3 solu-
tion (Sigma-Aldrich, Buchs SG, Switzerland) was injected once intravenously (i.v.) via the 
tail vein. The mice received either 35-mg/kg NaIO3 for RNA sequencing or 50-mg/kg 
NaIO3 for all the other experiments. The controls received i.v. the respective volume of 
0.9% NaCl (B. Braun Melsungen AG, Melsungen, Germany; 100 µL). The eyes were enu-
cleated three or ten days after treatment, whereas the serum was prepared after ten days 
only. The experiments were approved by the commission for involving animals in re-
search of the Canton of Bern, Switzerland (BE8/18) and in accordance with the European 
Community Council Directive 2010/63/EU and the ARVO Statement for the Use of Ani-
mals in Ophthalmic and Vision Research.  
4.2. Retinal Morphometric Analysis 
A morphometric analysis was performed on H&E (a haematoxylin (Mayer’s he-
malum, Cat. # 09249.0500; Merck, Darmstadt, Germany) and eosin (Cat. # X883.2; Roth, 
Arlesheim, Switzerland) stained cross-section of murine eyeballs. To assess the number of 
photoreceptor cells, the nuclei per longitudinal stretches of 60 µm were counted manually 
at intervals of 250 µm using ImageJ software (Version 1.51n; National Institutes of Health, 
Bethesda, MD, USA). 
4.3. RNA Sequencing 
The sensory retina and RPE were harvested separately and immediately frozen in 
liquid nitrogen. The samples were kept at −80° C until RNA extraction with the RNAeasy 
Mini QIAcube kit (Cat. # 74116; Qiagen, Hilden, Germany) in the QIAcube (Cat. # 9001293; 
Qiagen). The samples were homogenised in the RLT buffer from the kit with the addition 
of 1% β-Mercaptoethanol (Cat. # 63689; Merck, Darmstadt, Germany) inside a TissueLyser 
II (Cat. # 1102664; Qiagen) with the addition of a stainless-steel bead, 5 mm in diameter 
(Cat. #69989; Qiagen). RNA quality control was performed on an Experion Automated 
Electrophoresis station (Cat. # 7007010; Bio-Rad Laboratories, Hercules, CA, USA), and 
the Experion RNA HighSens Analysis kit (Cat. # 7007105, Bio-Rad Laboratories, Munich, 
Germany) according to the manufacturer’s protocols.  
The samples were prepared with the HiSeq PE Rapid Cluster Kit v2 and HiSeq Rapid 
SBS Kit v2 with 50 cycles (Cat. PE-402-4002 and FC-402-4022, Illumina, San Diego, CA, 
USA) and sequenced with the HiSeq 2500 system (Cat. #SY-401-2501; Illumina) on rapid 
run mode. The sequencing reads were mapped on the mouse genome draft GRCm38 us-
ing the program STAR [33] and the Ensembl gene models (version 92). Genes with a low 
mean number of counts across the samples (<150) were removed, and about 14k genes 
passed this filtering step. A differential gene expression analysis was performed in R us-
ing the limma library [34–36]. The gene counts were converted into log2 CPM (log2 counts 
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per million), and the dataset was assessed for inter- and intragroup variability and expres-
sion correlation profiles (pairwise Pearson correlation) in order to evaluate the data qual-
ity. 
4.4. Quantitative Real-Time Polymerase Chain Reaction (qPCR) 
After enucleation, the retinas of both mouse eyes were dissected, and the mRNA was 
isolated using a NucleoSpin RNA Kit (Macherey-Nagel, Düren, Germany). Eluted mRNA 
was reverse-transcribed to cDNA using the QuantiTect Reverse Transcription Kit (Qiagen, 
Hilden, Germany). To analyse the gene expression, qPCR was conducted using a Rotor-
Gene Q Real-time PCR Cycler, Rotor Gene SYBR Green Kit (all Qiagen) and primers (Table 
1; Metabion, Planegg, Germany). For amplification, 40 cycles consisting of an annealing 
temperature at 60 °C for 10 s was applied. The expression of isocitrate dehydrogenase 3 sub-
unit beta (idh3b) was used for normalisation of the gene expression [21]. The fold change 
in the expression between the control and treatment groups was subsequently calculated 
employing the ΔΔCt method and transformed to the logarithm to base 2. The data are 
shown as log2(ΔΔCt). 
Table 1. qPCR primer. 

























R: TGGGATGGGGAAGGAAATGC 60 




















R: CCATGTCTCGAGTCCGTACC 60 
4.5. Simple Western™ Protein Analysis 
Frozen retinas were thawed on ice and transferred to Precellys tubes (soft tissue ho-
mogenising CK14, Cat. # KT03961-1-203.0.5; Bertin Technologies SAS, Montigny-le-
Bretonneux, France) and 1x RIPA buffer (#20-188; Sigma, Burlington, VT, USA). Protease-
inhibitor mix (1x cOmplete EDTA-free Mini, Cat. # 11836170001; Roche Diagnostics, Rot-
kreuz, Switzerland) was added for homogenisation in the Precellys 24 system (Bertin 
Technologies SAS) for 15 s with 5500 rpm twice, with intermittent cooling on ice. The ho-
mogenates were transferred into Protein Lo-Bind tubes (Cat. # 0030108434; Eppendorf, 
Hamburg, Germany) and centrifuged at 16,000× g at 4 °C for 3 min. The supernatant was 
collected in fresh Protein Lo-Bind tubes and processed for the protein concentration anal-
ysis with BCA Protein Assay Kit Pierce™ (Cat. # 23225; Thermo Fisher Scientific, Wal-
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tham, MA, USA) and afterwards diluted to 1 mg/mL in aLISA buffer (AlphaLisa Immu-
noassay Buffer 10x, Cat. # AL000F; PerkinElmer, Waltham, MA, USA). A total volume of 
35 µL was prepared, and the samples were aliquoted into 6-µL aliquots into Simport strips 
(amplitude PCR reaction strips 8× 0.2 mL, attached domed cap #T320-3N Simport, Beloeil, 
QC, Canada) and frozen at −80 °C until use. As a positive control, normal mouse serum 
(Cat. # NMS, Complement-Technology, Tyler, TX, USA) was also prepared as a 1:50 dilu-
tion in aLISA buffer and frozen at −80 °C. Protein samples and primary and secondary 
antibodies were loaded into a 96-well plate and analysed by capillary electrophoresis us-
ing a 12–230-kDa separation matrix on a Peggy Sue device, as described by the provider 
(Cat. # 004-800, ProteinSimple, San Jose, CA, USA). The working solutions were diluted 
with Mastermix (according to the preparation datasheet of the provider) so that the final 
concentration for the lysates was 0.8 mg/mL. 
The following commercially available antibodies were tested for specificity and op-
timised for the system: rabbit anti-C3 (Cat. #ab200999; Abcam, Cambridge, UK), goat anti-
C1s (Cat. #A302; Quidel Corporation, San Diego, CA, USA), rat anti-C4 (Cat. #ab11863, 
Abcam), goat anti-CFB (Cat. #A311; Quidel Corporation), sheep anti-CFH (Cat. #AF4999; 
R&D Systems, Minneapolis, MN, USA), rabbit anti-GAPDH (Cat. #G9545; Sigma-Al-
drich), anti-goat HRP (Cat. #043-522-2; ProteinSimple, San Jose, CA, USA), anti-sheep 
HRP (Cat. #HAF016; R&D Systems), anti-rabbit HRP (Cat. #040-0656; ProteinSimple) and 
anti-rat HRP (Cat. #HAF005; R&D Systems). 
4.6. Western Blot 
Protein extraction from the retinal tissue was carried out using T-PER buffer (Thermo 
Fisher Scientific) with the addition of 1% protease and 1% phosphatase inhibitor (Sigma-
Aldrich). Protein samples were separated by SDS-PAGE using denatured, reducing con-
ditions. The proteins were transferred onto a PVDF membrane. The membrane was 
blocked with blocking buffer (5% bovine serum albumin (BSA) and 0.1% Tween 20 in Tris-
buffered saline) and primary antibodies (goat anti-C3d antibody (Cat. #AF2655; R&D Sys-
tems) or rabbit anti-GAPDH antibody (Cat. #CSB-PA00025A0Rb; Cusabio Technology 
LLC, Houston, TX, USA)) were added overnight. Detection was performed using second-
ary antibodies (anti-goat IgG-POD #SBA-6442-05, anti-rabbit-POD #711-546-152 (Dianova 
GmbH, Hamburg, Germany)) and the Lumi-Light Western Blotting Substrate (Cat. # 
12015200001; Sigma-Aldrich) and imaged by the FluorChem FC2 Imaging System (Appli-
Chem, Darmstadt, Germany). Western blot images were edited in Adobe Photoshop CS6 
(San Jose, CA, USA) and analysed for signal intensity using ImageJ software (National 
Institutes of Health). 
4.7. Immunohistochemistry Staining 
Determination of the complement expression in the retina and RPE was performed 
as previously described [37,38]. Paraformaldehyde-fixed, cryoprotected and embedded 
eyes were cut into 20-µm slices, permeabilised, blocked with 5% goat or donkey se-
rum/0.1% Tween20 in phosphate-buffered saline (PBS) and incubated with primary anti-
bodies specific for C3d (Cat. #AF2655; R&D Systems), C1s (Cat. #14554--1--AP; Pro-
teintech, Rosemont, IL, USA), C4 (Cat. #A205; Complement Technologies, Tyler, TX, 
USA), IBA (Cat. #019-19741; Wako Chemicals, Neuss, Germany) and glial fibrillary acidic 
protein (GFAP; G3893, Sigma-Aldrich) diluted in blocking buffer. The sections were la-
belled with fluorescence-conjugated secondary antibodies (anti-mouse Cy5 (Cat. #115-
607-072; Dianova) & anti-goat Cy3 (Cat. #705-165-147; Dianova) and anti-rabbit AF-488 
(Cat. #A-21206; Invitrogen)) and DAPI nucleic acid stain (Cat. # 62248c; Invitrogen). All 
images were taken with a confocal microscope (VisiScope; Visitron Systems, Puchheim, 
Germany). 
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4.8. C3a ELISA 
Nunc-Immuno MaxiSorp 96-well plates were coated with anti-mouse C3a antibody 
(Cat. #558250; 3 µg/mL, BD Biosciences) in a phosphate buffer (pH 6.5) at 4 °C overnight. 
The plates were blocked using 1% BSA in PBS. Sera of the control and NaIO3-treated mice 
(1:8000 and 1:16,000), as well as normal mouse serum (1:1000–1:64,000 for the standard 
curve) were incubated in a sample buffer (0.1 mg/mL nafamostat mesylate in 1% 
BSA/PBS). Detection was performed with the anti-mouse C3a-biotin antibody (Cat. 
#558251, 2 µg/mL in PBS, BD Biosciences), streptavidin-HRP and 3,3′,5,5′-tetramethylben-
zidine (TMB). The optical density (absorption) was measured photometrically at 450 nm 
using VarioScan Flash (Thermo Fisher). 
4.9. Multiplex Cytokine ELISA 
The customised ProcartaPlex was performed according to manufacturer’s instruc-
tions (Invitrogen, Carlsbad, CA, USA). In brief, the magnetic beads for murine CCL3, 
CCL4, CCL5, IL-1β and VEGF-A were incubated with 1:2 diluted serum samples over-
night. An antigen-specific biotinylated detection antibody mixture was applied following 
the streptavidin–phycoerythrin solution as a detection reagent. The assay was measured 
on Luminex™ MAGPIX™ (Austin, TX, USA) to determine the mean fluorescence inten-
sity (MFI) for each chemokine or cytokine. 
4.10. Statistical Analysis 
Data were analysed statistically using GraphPad Prism 6 Software. To determine the 
statistical differences between the two groups unpaired, the nonparametric Mann–Whit-
ney t-test was used. To compare three or more different treatment groups, ordinary one-
way analysis of variance (ANOVA) with Tukey’s multiple comparisons was performed. 
For a statistical analysis of the morphometrical data, a two-way ANOVA with Bonferroni 
post-tests was performed. p-values < 0.05 were considered statistically significant. 
5. Conclusions 
Retinal degeneration induced by NaIO3 in mice can serve as a model mimicking ret-
inal inflammatory sequence. The data could help to decipher possible mechanisms of ret-
inal degenerative and inflammatory processes in human patients. We showed that soluble 
immune proteins, complement proteins and cytokines/chemokines are time-dependently 
altered locally in this mouse model. However, using a mouse model to understand the 
pathologies in a different species always has limitations. Therefore, our data, first of all, 
showed the situation in the murine environment. Nevertheless, as the induced retinal de-
generation follows the main cell death pathways such as necrosis and apoptosis, a gener-
alisation for mammalian retina might be appropriate. In sum, this body of evidence sup-
ports the hypothesis that a local immune response plays a pivotal role in retinal degener-
ation. 
Supplementary Materials: The following are available online at www.mdpi.com/arti-
cle/10.3390/ijms22179218/s1, Figure S1: (A) Patchy RPE loss and photoreceptor degeneration in the 
NaIO3-induced damage area (left). The dashed line depicts the transition to the area with physio-
logical morphology (right). H&E staining of murine retinal cross-section three days after NaIO3 
treatment. Scale bar: 100 µm. (B) No mouse IgG were detected in the retinal tissue using Simple 
WesternTM technology and anti-mouse IgG-HRP (mouse serum as positive control) three days after 
NaIO3 treatment. Figure S2: Transcript quantity of components of the complement pathway (GO: 
0006956) investigated in control (blue) or NaIO3-treated (red) retina using RNA-Seq analysis three 
days after NaIO3 treatment. Figure S3: (A) Full Western blot is shown for C3 detection in untreated 
retinas and three as well as ten days after NaIO3-treatment. (B-F) Full Simple Western™ blots are 
shown for C3, C1s, C4, CFB and CFH detection in untreated retinas and three days after NaIO3-
treatment. Figure S4: NaIO3-treatment does not alter systemic complement activation. Complement 
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activation product, anaphylatoxin C3a, is analyzed in an ELISA comparing serum samples of un-
treated and NaIO3-treated mice, ten days post-treatment. Systemic C3a levels of treated mice do not 
differ significantly from those of untreated animals 
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